Skip to main content
. 2008 Apr 3;111(12):5477–5485. doi: 10.1182/blood-2008-01-132837

Table 1.

Effect of end-induction MRD on outcome by therapeutic protocol and NCI risk group

Study/risk group 5-y EFS, % ± SE (no.)
MRD MRD+ (> .01%)*
9904/SR 95 ± 1 (668) 64 ± 7 (105)
9905/SR 89 ± 2 (464) 59 ± 6 (119)
9905/HR 79 ± 4 (295) 33 ± 8 (74)
9906/HR 72 ± 5 (161) 34 ± 8 (85)
*

P < .001 for all comparisons.

Also includes CNS3 patients, patients with testicular disease, or patients with MLL rearrangements.